Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.39 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718831 | 0.95 | TAAR1 (0.45) | HTR7TAAR1KDM4EALDH1A1BCHE | |
| SCHEMBL13718623 | 0.88 | ADORA2A (0.46) | NPC1RAB9AHTR7TAAR1KDM4E | |
| SCHEMBL13718775 | 0.88 | LMNA (0.45) | NPC1RAB9ATAAR1ALDH1A1BCHE | |
| SCHEMBL13717813 | 0.88 | KDM4E (0.40) | HTR7TAAR1KDM4EGAAHTT | |
| SCHEMBL13718482 | 0.88 | HTR7 (0.41) | HTR7TAAR1KDM4EALDH1A1BCHE | |
| SCHEMBL13718766 | 0.87 | NPC1 (0.41) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13718017 | 0.85 | ALDH1A1 (0.48) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13718539 | 0.85 | BCHE (0.38) | HTR7TAAR1KDM4EALDH1A1GAA | |
| SCHEMBL13718361 | 0.84 | HTR2C (0.45) | NPC1RAB9AHTR7TAAR1ALDH1A1 | |
| SCHEMBL13718212 | 0.84 | TAAR1 (0.40) | NPC1RAB9ATAAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278962-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759380-B2 | Certain heterocycles, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330011-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | NPC1 864/4885RAB9A 656/4885HTR7 513/4885 |
| US-20120289698-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | NPC1 864/4885RAB9A 656/4885HTR7 513/4885 |
| US-20160289211-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1S | NPC1 897/4885RAB9A 858/4885HTR7 321/4885 |
| US-20130060025-A1 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ZYX | NPC1 864/4885RAB9A 656/4885HTR7 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.